Garadacimab
Garadacimab Basic information
- Product Name:
- Garadacimab
- Synonyms:
-
- Garadacimab
- Research Grade Garadacimab (DHB88201)
- CSL312
- Research Grade Garadacimab
- Garadacimab (anti-Factor XII)
- CAS:
- 2162134-62-3
- MW:
- 0
- Mol File:
- Mol File
Garadacimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Garadacimab Usage And Synthesis
Uses
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research[1].
in vivo
In male and female cynomolgus monkeys, Garadacimab (0.5, 1, and 3 mg/kg i.v. and 6 and 20 mg/kg s.c. over 8 weeks) plasma concentrations increased in a dose-dependent manner[1].
Garadacimab has an inhibitory effect on FXII-mediated kallikrein activity. Furthermore, Garadacimab causes a clear dose-dependent prolongation of activated partial thromboplastin time (aPTT) with no associated effect on the prothrombin time[1].
References
[1] Dipti Pawaskar, et al. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). Clin Transl Sci. 2022 Mar;15(3):709-720. DOI:10.1111/cts.13192
[2] Helen Cao, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018 Oct;142(4):1355-1358. DOI:10.1016/j.jaci.2018.06.014
GaradacimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com